**Reviewer’s Comments**

******

***Mentha piperita*L.- A promising dental care herb mainly against cariogenic bacteria**

**Abstract:**

Oral diseases are considered from the major health problems and are not limited to dental caries and periodontal diseases but to various autoimmune conditions. Itsayurvedic therapy includes different plants used in management of toothache, sore throat, mouth sores, abscess, broken tooth and jaw, tooth sensitivity, mouth thrush, dental caries, gingivitis, tooth bleaching, dental anxiety, dental phobia and plants used for dental extraction. Peppermint (*Menthapiperita* L.), a sterile hybrid of the species *M. aquatica* L. and *M. spicata*, L. is considered one of the important aromatic herbs containing high amount of volatile oil used in dental care. The peppermint leaves have a characteristic, aromatic, strong odor and an aromatic, warm, pungent taste followed by a cooling sensation.The medicinal parts are the [essential oil](https://www.sciencedirect.com/topics/chemistry/essential-oil) extracted from the aerial parts of the flowering plant, the dried leaves, the fresh flowering plant and the whole plant. M. piperita L.is a perennial 50–90 cm high, normally quadrangular and a prototypical member of the mint family. The essential oil of *M.piperita*L.leaves is characterized by the presence of high percent of menthol (29-48%) in addition tomenthone (20-31%), and the different isomers of menthol in addition to other constituents.*M. piperita*L. is one of most promising species with antibacterial potential against cariogenic bacteria as *Streptococcus mutans*. Peppermint oil and leaves posses several other biological effects as antiseptic in oral preparations, antibacterial,antiviral, antifungal, antioxidant and antispasmodic effects. It is also used as a flavoringagent in food and pharmaceutical industry and oral preparations.

**Key words:**Mentha, menthol, dental caries, antibacterial, flavoring agent.

**INTRODUCTION**

Recently there is a great renewed interest for the reuse of differenttraditional drugs generally in therapy and especiallyfor oral and dental health.Various plants have high potential in the treatment of dental problems. The most commonly used medication for oral and dental health is *Mentha piperita*L..*Mentha piperita* L., a medicinally important plant belongs to the Family Lamiaceae**(African pharmacopoeia 1985)** and commonly known as Peppermint is a hybrid *of M. spicata* L. (spearmint) and *Mentha aquatic*L.. It was cultivated by the ancient Egyptians and documented in the Icelandic pharmacopoeia of the thirteenth century. It is widely grown in temperate areas of the world, particularly in Europe, North America and North Africa but nowadays cultivated throughout all regions of the world. The medicinal parts are the essential oil extracted from the aerial parts of the flowering plant, the dried leaves, the fresh flowering plant and the whole plant. Peppermint oil has a fresh, sharp, menthol smell, is clear to pale yellow in color and watery in viscosity. India is the world’s largest producer and exporter of mint oil**(Balakrishnan 2015).**It is used in the form of herbal preparation(s); infusion and tinctures; in addition to its use in different Pharmaceutical forms whether solid or liquid dosage forms**.**

**Synonyms**

*Mentha piperita* (L.) Huds., *M. piperita* Stokes, *M. balsamea* Willd. **(African pharmacopoeia 1985).**

**Taxonomy(Edwars 1944)**

**Kingdom:** Plantae.

**Division :**Angiospermae.

**Class:**Dicotyledoneae.

**Sub class**: Sympetalae.

**Order:**Tubiflorae.

**Sub order**: Verbenineae.

**Family:** Labiatae ( Lamiaceae).

**Sub family:**Stachydoideae

**Tribe:**Satureieae.

**Genus:***Mentha*

**Species:***Mentha piperita* Linnaeus (Peppermint).

**Varieties:***Mentha piperita* var. *officinalis* Sole (White Peppermint).

*Mentha piperita* var. *vulgaris* Sole (Black Peppermint).

**Localnames around the world**

**Arabic:** Nana; **Bogota:** Yerba Buena;**Brazil:**Nortelapimento; **Chinese:** Po Ho;**Danish:**Pebermynte; **Dutch:**Pepermint;**English:** Brandy Mint, Pepper Mint;**French:**Menthe, Menthe anglaise; **Hungarian:**Borsus menta;**Italian:**Menta piperita; **Mexico:** Menta piperita;**NorthAmerica:**Lamb Mint, Brandy Mint, Lam Mint,Peppermint;**Norwegian:**Peppermynte;**Polish:**Pepparmunta;**Portuguese:**Hortelanapimentosa;**Russian:**Myataperechnaya;**Spanish:**Mentainglesa,Menta Piperita;**Swedish:**Pepparmynt; **Turkish:** Nana;**Uruguay:**Menta; **Indian:**Hindi, Bengali, Gujarati, Punjabi, Urdu, Marathi, Tamil and **Telugu:**Pudina; **Kashmiri:**Pudyanu; **Malayalam:**Puthina**(Rita P. and Animesh D.K. 2011)**.

**Pharmacognostical characters**

*M. piperita*L.is a perennial 50–90 cm high, normally quadrangular and a prototypical member of the mint family **(Briggs 1993)**.The usually branched stems are often purplish or tinged violet but sometimes they are gray-tomentose. The dark or light green leaves are short-petioled, oblong-ovate and serrate with their margins finely toothed. The flowers are purple or pinkish having false spikes with numerous inconspicuous bracts and rarely bear seeds **(Clark and Menory, 1980)**. The plant is generally sterile and spreads by means of runners. The plant grows in a sunny side and prefers acid, neutral and basic, light, medium soils but can also grow in heavy clay soil **(Bradley 1992)**.

**Leaf anatomy**

Leaves being the most important part from which oil isextracted, the anatomical characters are relevant. Upperepidermis composed of large, clear epidermal cells with sinuous, verticalwalls and possessing few or no stomata, few glandular trichomes present;palisade parenchyma, comprising a layer of columnar cells rich in chloroplasts;spongy parenchyma, of 4-6layers of irregularly shaped chloroplastidcontaining cells and intercellular airspaces. Lower epidermis of small epidermalcells withsinuous, vertical walls and numerous diacytic stomata; in the region ofveins and midrib, exhibits non-glandular and glandular trichomes as outgrowths;non-glandular trichomes uniseriate, papillose, 1-8celled; glandulartrichomeshave 1-2celled stalk and 1-8celled glandular head containing the essential oil.Calcium oxalate crystals absent**(*Mentha piperita* folium - WHO Herbal Monograph 2011)**.

**Phytochemistry of *Menthapiperita* L.**

In *M. piperita*essential oil 26 components were detected and identified (97.7%). Menthol (37.4%), menthyl acetate (17.4%) and menthone (12.7%) were the main components in this oil are Sabinene, β-Myrcene, 3-Octanol, α-Terpinene, *p*-Cymene, Limonene, 1,8-Cineole, *cis*-Ocimene, *trans*-Ocimene, γ-Terpinene, α-Terpinolene, Linalool, Menthone, Menthofuran, Pulegone, Piperitone, β-Bourbonene, β-Caryophyllene, (*Z*)-β-Farnesene, Germacrene D, Bicyclogermacrene, Germacrene A, δ-Cadinene, Viridiflorol**(Soković M.D. 2009)**.

Other constituents include flavonoid glycoside (eg. Narirutin,Luteolin-7-o-rutinoside, Isorhoifolin and Hesperidin etc), polyphenols (e.gRosmaric acid, Eriocitrin, Cinamic acid, Caffeicacid and Narigenin-7-oglucoside); luteolin-diglucoronide anderiodictyol glucopyranosyl-rhamnopyranoside were also purifiedfrom aerial parts of mint**(Loolaie M. 2017)**.

**Quality Control**

**General identity tests**

Thin-layer and gas chromatography for characteristic monoterpene profiles**(British pharmacopoeia 1995)(European pharmacopoeia 1996)**

**Purity tests**

**MICROBIOLOGICAL**

Tests for specific microorganisms and microbial contamination limits are as described in the WHO guidelines on quality control methods for medicinal plants **(WHO 1998)**.

**CHEMICAL**

**Acid value:** not more than 1.4**(British pharmacopoeia 1995)(European pharmacopoeia 1996)**.

**Relative density:** 0.900–0.916 **(British pharmacopoeia 1995)**.

**Refractive index:** 1.457–1.467 **(British pharmacopoeia 1995)**.

**Optical rotation:** -10° to -30° **(British pharmacopoeia 1995)**.

**Solvent solubility:** miscible with ethanol (96%), ether and methylene chloride **(European pharmacopoeia 1996)**.

**Pesticide residues**

The recommended maximum limit of aldrin and dieldrin is not more than 0.05mg/kg **(European pharmacopoeia 1996)**and the WHO guidelines on quality control methods for medicinal plants **(WHO 1998)** and pesticide residues **(WHO 1998)**.

**Heavy metals**

For maximum limits and analysis of heavy metals, consult the WHO guidelines on quality control methods for medicinal plants **(WHO 1998)**.

**Radioactive residues**

Where applicable, consult the WHO guidelines on quality control methods for medicinal plants **(WHO 1998)** for the analysis of radioactive isotopes.

**Chemical assays**

The monoterpene content determined by gas chromatography should be 1,8- cineole (6–14%), limonene (1–5%), menthone (14–32%), menthofuran (1–9%), isomenthone (2–10%), menthyl acetate (3–5%), menthol (30–55%), pulegone (not more than 4.0%) and carvone (not more than 1.0%). The ratio of 1,8- cineole to limonene should be greater than 2.0 **(British pharmacopoeia 1995)(European pharmacopoeia 1996)**).

***Mentha piperita*L. and dental care:**

*M. piperita*L. is used in making oral dentifrices as it can provide overall freshness in breath and also keep away bad breath**(Balakrishnan 2015)**. Mentha is used in preparations used as mouthwashes to remove dental plaque **(Bhat N. 2013)(Henley-Smith C.J. 2013)**.

The aqueous extract of *Mentha piperita* (linn.) has inhibited the initiation and promotion of oral dysplastic lesions**(Kasem R.F. 2014)**and for treatment of inflammation of the oral mucosa**(Brahmi F. 2017)**.

**Anti-bacterial effect against cariogenic bacteria:**

The oral cavity contains a wide variety of oral bacteria, but only a few specific species of bacteria are believed to cause dental caries namely *Streptococcus mutans*, *Lactobacillus acidophilus*, *Actinomyces viscosus*, *Nocardia* spp. *Streptococcus mutans* are most closely associated with caries **(Kabra P. 2012)**.The essential oil of *M. piperita*L. has strong antibacterial activity against *S. mutans* and lactobacilli responsible for dental caries**(Freires I.A. 2015)(Chaiya A. 2013)(Kermanshah H. 2014)(Henley-Smith C.J. 2013)**Essential oil and peppermint leaves are used for making mouth rinses and gels that affect the periodontal bacteria**(Petrović M.S. 2015).**

*M. piperita*has been proved to have antimicrobial activity against oral microorganisms and can be used as an alternative medicine and as an adjunct to the conventional therapy, which would help the countries which are developing and having financial constraints and with limited oral health care facility for the concerned population**(Raghavan R. 2018)**.Menthol is also used as a mouthwash which is effective as an anti-plaque and anti-gingivitis agent**(Ali N.A. 2015)**.

**Traditional Uses**

**-** Peppermint has traditionally been used as a rubefacient**(Hawthorn M 1988).**

- The essential oil from *Mentha* is used topically to treat oral mucosal inflammation and also an antimicrobial and an ingredient in many analgesic creams. Approved for internal use, the oil from *Mentha* is also used to treat bile duct discomfort, irritable bowel syndrome, myalgia and neuralgia, inflammation of the oral mucosa, discomfort from menstrual cramps, secondary amenorrhea and oligomenorrhea, and diverticulitis and is used as an anti-inflammatory and expectorant**(Fatiha Brahmi 2017)**.

- In India, Peppermint oil (as well as peppermint leaf) has been used internally as an antispasmodic (upper gastrointestinal tract and bile ducts) and to treat irritable bowel syndrome, catarrh of the respiratory tract, and inflammation of the oral mucosa. Externally, peppermint oil has been used for myalgia and neuralgia, to relieve menstrual cramps and used externally for neuralgia, myalgia, headaches, migraines, and chicken pox. In addition, Peppermint plants have been used for many conditions, including loss of appetite, common cold, bronchitis, sinusitis, fever, nausea, vomiting, and indigestion**(Fatiha Brahmi 2017)**.

- In Finland, Peppermint uses include irritable bowel syndrome, flatulence, indigestion, nausea, vomiting, cough, and bronchitis**(Fatiha Brahmi 2017).**

**-** While in USA,the odors of peppermint serve as central nervous system stimulant and are used to decrease fatigue**(Fatiha Brahmi 2017)**.

**Pharmacological Properties of*Mentha piperita*L.**

* **Anti-bacterial activity:**

Peppermint oil and different extracts of *Mentha piperita* possess potent antibacterial activity against some Gram-positive and Gram-negative bacterial strains**(Singh R. 2015)(GO¬ KALP IúSüCAN 2002)**and its ability to on the adherence and retention of bacteria in dental biofilm**(Abdul Rahim Z.H. 2014).**

* **Anti-microbial activity:**

Menthol is virucidal against Influenza, Herpes and other viruses in vitro**(Eccles R. 1994).** Aqueous extracts of *M. piperita*L.,*M. piperita*L. oil and menthol have mild antibacterial effects against both Gram-positive and Gram-negative bacteria **(El-Kady IA 1993)(Pattnaik S 1996)(Moleyar V 1992)(Singh R. 2015)**. *M. piperita*L. extracts are bacteriostatic against *Streptococcus thermophilus* and *Lactobacillus bulgaricus***(Pattnaik S 1997)**. Menthol is bactericidal against strains like *Staphylococcus pyogenes*, *S. aureus*, *Streptococcus pyogenes*, *Serratia marcescens*, *Escherichia coli*, and *Mycobacterium avium***(El-Kady IA 1993)(Pattnaik S 1997)(Agarwal R. 2014)**. Menthol and peppermint oil are fungicidal against *Candida albicans***(Samber N. 2014)**, *Aspergillus albus* and dermatophytic fungi**(El-Kady IA 1993)**.

* **Anti-oxidant activity:**

The oil and different extracts of *M. piperita* exhibit significant antioxidant activity **(Singh R. 2015)**

* **Cardiovascular activity:**

*M. piperita*is said to have vasodilating properties on some animals. It has a lowering effect on the heart rate and the systolic pressure. Relaxation of bronchial smooth muscles , increase in the ventilation are also other cardiovascular effects of peppermint oil. **(Robbers JE 1999).**

- **Gastrointestinal Benefits**:

*M. piperita*L. is used for treatment of non-obstructive dyspepsia without any known side effects. It improves the gastric emptying rate. There is a significant antiemetic effect of peppermint in reducing postoperative nausea for patients with very sensitive gag reflexes**(Balakrishnan 2015)**.

* **Neuropsychiatric Effects:**

 Some studies have suggested that peppermint is a central nervous system stimulant. Studies have been conducted on the effectiveness of aromas on cognitive performance, perceived physical workload, and pain responses were conducted based on possible changes in the brain activity**(Balakrishnan 2015)**.

* **Endocrine Effects:**

Certain researches have proved that there was a statistically significant increase in the secretion of endocrine hormones**(Robbers JE 1999).** In one study there was a noted segmental maturation arrest in the somniferous tubules however, the effects of *M.spicata*L. extended from maturation arrest to diffuse germ cell aplasia in relation to the dose. Other than this there are not many significantly known effects on the human endocrine system.

* **Effect on Skin and Mucous Membrane**

*M. piperita*L. is said to be a good analgesic to be applied topically and also a coolant for the skin. *M. piperita*L. oil stimulates cold receptors on the skin and dilates blood vessels, causing a sensation of coldness and an analgesic effect **(Robbers JE 1999).** Menthol is a topical vasodilator that enhances the absorption of other topical skin medications. It is said that menthol enhances the absorption of cortisone, mannitol, indomethacin, morphine hydrochloride, and propranolol **(El-Kady IA 1993)(Pattnaik S 1997)**. Menthol moderates oral sensations of warmth and coldness**(Moleyar V 1992)(Janssen AM 1986)**. In low concentrations, topical application of menthol causes a cooling sensation, while in high concentrations it causes irritation and local anesthesia**(Raudenbush B 2002)**. It also increases cutaneous blood flow, muscle temperature, and skin temperature after topical application of the oil. Some studies have claimed that menthol has reduced histamine induced irritation and itching.

* **Immune modulation**

Menthol has anti-inflammatory effects when applied topically. In one study it was claimed that it could suppress antigen induced allergies. Menthol also has a property of inhibiting cutaneous anaphylaxis that’s mediated by IgE antibody**(Balakrishnan 2015)**.

* **Anti-spasmodic activity:**

 Previous studies have shown that various kinds of mint were effective in reducing muscle pain **(Fox N. 1027)**muscle relaxation, and reduce fatigue. Until now, many researches have been done on the effectiveness of various kinds of natural products in the improvement of sport performances. Mint is a herb which is well known for its antispasmodic, painkilling **(Eccles R. 1994)(Murray MT. 1995)**, anti-inflammatory, antispasmodic, decongestant, and antioxidant effects **(Hoffman D. 1996)**. Peppermint is one of the mentha species (i.e., *M.piperita*, peppermint oil, *M. arvensis*, cornmint oil **(Bove M. 1996)**. Menthol and menthone are the major components of the peppermint essential oil. External application of peppermint extract raised the pain threshold in human **(Blumenthal M. 1998)**. Peppermint aroma was also effective on perceived physical workload, temporal workload, effort, and anxiety **(Fleming T. 1998)**. According to certain in vitro studies conducted on the antispasmodic effect of peppermint oil, peppermint relaxes gastrointestinal smooth muscle spasm by reducing calcium influx in both guinea pig large intestine and rabbit jejunum.

* **Anti-headache activity**

Since ancient times, herbal therapy has been used as treatment for headache disorders. Consumption of peppermint andderivatives is the best target for headache therapy in combination in relieving patients’ headache pain**(Loolaie M. 2017)**.

* **Effect on hepatic enzymes**

The aqueous extract ofpeppermint (at concentration 2% v/v) can modulate of phase Iand phase II drug metabolizing enzymes. In phase I, a varietyof enzymes act to introduce reactive and polar groups into theirsubstrates. Phase II biotransformation reactions generallyserve as a detoxifying step in drug metabolism.The peppermint alcoholic extract ameliorated theadverse effects of CCl4 on growth performance and liver function,therefore it was indicated that it might be useful for the preventionof oxidative stress-induced hepatotoxicity **(Loolaie M. 2017)**.

* **Radioprotective Effects**

The effectiveness of peppermint alcoholic extract against radiation induced morbidity and mortality using the optimum dose of 100 mg/kg for 3 consecutive days. The antioxidant and free radical scavenging activities of leaf extract of peppermint are directly related to its mechanism of radiation protection.Several mechanisms such as antioxidant activity, immune response,and enhanced recovery of bone marrow have been suggested forchemoprevention and radioprotection of peppermint extracts**(Loolaie M. 2017)**.

**Adult Dosing (Age<18)**

**Oral dosage:**

* **Colonic spasm:**8mL of peppermint oil solution has been used.
* **Cough:**75% menthol in eucalyptus oil has been used to suppresscough induced by 33µM citric acid**(Morice 1994)**.
* **Digestive disorders:**0.2-0.4mL of peppermint oil has been usedthree times daily in dilute preparations or suspension **(Giachetti 1986).**
* **Esophageal spasm:**5 drops of peppermint oil in 10mL of waterhas been used **(Pimentel 2001).**
* **Gastric spasm:** 16mL of peppermint oil dissolved in hot water andinfused intra-luminally has been used duringupper endoscopy **(Hiki 2003)**.
* **Irritable bowel syndrome (IBS):**0.2- 0.4mL of peppermint oil or 187-374mg of peppermint oil in a thixotropic gel) has been used three times daily15-30 minutes before meals for up to one month **(Balakrishnan 2015)**, 180-200mgenteric-coated peppermint oil has also been used **(Grigoleit 2005)**.
* **Sore throat:**Lozenges that contain 2-10mg of peppermint oil havebeen used, according to secondary sources.
* **Vomiting:**3-6g of leaf and 5-15g of tincture have been used as anantiemetic, according to secondary sources.

**Other traditional dosing:**

The following doses of peppermint havebeen used traditionally for various indications of gastrointestinaltract, gall bladder, and bile duct, and there is no proven dosing regimen**(Keifer D. 2007)**:

* **Dried extract:**2-4g of dried herb extract three times daily.
* **Infusion:**1.5-3g of peppermint oil in 150mL of water three timesdaily.
* **Spirits:**(10% oil and 1% leaf extract) 1mL (20 drops) withwater.
* **Tea:**3g of dried peppermint leaves in 250mL of boilingwater, approximately 3-4 cups daily between meals for gastrointestinal symptoms.
* **Tincture:**(1:5 preparation 45% ethanol) 2-3mLthree times daily.

**Topical dosage:**

* **Tension headache:**A combination of eucalyptus and peppermintoil (19% in ethanol solution) has been applied to the temples at theonset of the symptoms and applied hourly across the forehead andtemples, and repeated every 15-30 minutes **(Gobel 1996)**.
* **Post-herpetic neuralgia:**2-4 drops of peppermint oil (standardized to 10% menthol) massaged in skin 3-4 times per day has beenused **(Davies 2002)**.

**Inhalation dosage:**

**Congestion:**Traditionally, 3-4 drops of oil added to hot water andinhaled has been used to relieve congestion. Alternatively, 62.5mgmenthol in 1mL petrolatum has been applied and inhaled in treating nasal congestion **(Eccles 1990)**.

**Parenteral dosage**

**Caution:**From one case study, peppermint oil should not be injected, as it may cause pulmonary edema by direct toxicity and anincrease in pulmonary vascular permeability **(Behrends 2005)**.

**Caution:**Avoid topical use of peppermint oil around the facial orchest areas of infants and young children, especially around thenose, because the menthol constituent can induce apnea, laryngealand bronchial spasm, acute respiratory distress with cyanosis, orrespiratory arrest if applied directly to the nasal and the chest areas**(Wyllie 1994)**.

**Toxicological Investigations**

- The oral LD50 in Wistar male rats was found to be 4.4g/kg after 24hours and 2.4g/kg after 48 hours **(Eickholt 1965)**.

- The intraperitoneal LD50 ofpeppermint oil U.S.P. was determined to be 819mg/kg after 24hours**(Eickholt 1965)**. Rats administered peppermint oil and pulegone (a constituent of peppermint oil) up to 100-160mg/kg body weight perday developed brain lesions and encephalopathy after 28 days**(Olsen P. and Thorup I. 1984)**. Pulegone, at doses of 80-160mg for 28 days, induced atonia,weight loss, decreased blood creatinine, and histopathologicalchanges in the liver in an animal study **(Thorup 1983)**. Ataxia and convulsions have occurred in single doses of 3, 4, and 5g/kg of peppermint oil in an animal study **(D. 1989)**. Cyst-like spaces in the whitematter of the cerebellum were observed after 90 days of peppermint oil administration at doses of 10, 40, 100mg/kg body weightper day in an animal study **(Thorup 1983)** In rats given menthone orally,there was a decrease in creatinine, and increases in alkaline phosphatase, bilirubin, and liver and spleen size **(Madsen 1986)**. The no-effectlevel was < 200 mg menthone per kilogram of body weight per day.In one case study, injection of peppermint oil resulted in pulmonary edema and acute lung injury, presumably due to direct toxicity and a resultant increase in pulmonary vascular permeability **(Behrends 2005)**.

**Conclusion**

Concerning the importance of Peppermint in the remedy of dental caries, it can be considered as one of the potent and highly safe drugs used for their treatment due to its effective antibacterial activity against cariogenic bacteria. It has a bright future in this field for its great benefits and its safety for use in humans without any considerable side effects or contraindications.

**References:**

* Abdul Rahim Z.H., S. S., Ismail W.N.H.W, Harun W.H.W. and Abdul Razak F. (2014). "The Effect of Selected Plant Extracts on the Development of Single-Species Dental Biofilms." Journal of the College of Physicians and Surgeons Pakistan**24**(11): 796-801.
*
* Agarwal R., S. C., Yeluri R. and Chaudhry K. (2014). "Prevention of Dental Caries-Measures beyond Fluoride." Oral Hygiene & Health**2**(1): 1-6.
*
* Ali N.A., A. M. J. a. A.-B. F. H. (2015). "Evaluation of Potential Effect of Menthol Solution on Oral Hygiene Status of Dental Students in a University in Iraq." Tropical Journal of Pharmaceutical Research**14**(4): 687-692.
*
* Balakrishnan, A. (2015). "Therapeutic Uses of Peppermint –A Review " J. Pharm. Sci. & Res.**7**(7): 474-476.
*
* Behrends, M., Beiderlinden, M., and Peters, J. (2005). " Acute lung injury after pepper-mint oil injection." Anesth. Analg.**101**(4): 1160-1162.
*
* Bhat N., M. R., REDDY J.J., OZA S. and VINAYAK K. M. (2013). "EVALUATION OF EFFICACY OF CHLORHEXIDINE AND A HERBAL MOUTHWASH ON DENTAL PLAQUE: AN INVITRO COMPARATIVE STUDY." International Journal of Pharma and Bio Sciences**4** (3): 625-632.
*
* Bradley, F. (1992). Rodale’s All-New Encyclopedia of Organic Gardening. Emmaus. Pennsylvania, USA, Rodale Press**:** 390.
*
* Brahmi F., K. M., Mohamed C. and Pierre D. (2017). Chemical Composition and Biological Activities of Mentha Specie. Aromatic and Medicinal Plants - Back to Nature.
*
* Briggs, C. (1993). "Peppermint: medicinal herb and flavouring agent." CPJ**126**: 89-92.
*
* Chaiya A., S. S., Chuakul W. and Temsiririrkkul R. (2013). "Screening for Dental Caries: Preventive Activities of Medicinal Plants against Streptococcus mutans." journal of Pharmaceutical Sciences**40**(1): 9-17.
*
* D., H. (1996). The complete illustrated holistic herbal. M. Rockport, Element Books Inc.
*
* D., M. U. a. S. C. (1989). "Toxicological evaluation of peppermint oil in ro-dents and dogs. ." Medical Science Research**17**(11): 499-500.
*
* D.K., R. P. a. A. (2011). " An Updated Overview On Peppermint (Mentha piperita) AN UPDATED OVERVIEW ON PEPPERMINT (MENTHA PIPERITA L.)." IRJP**2**(8): 1-10.
*
* Davies, S. J., Harding, L. M., and Baranowski, A. P. (2002). "A novel treatment ofpostherpetic neuralgia using peppermint oil." Clin J Pain**18**(3): 200-202.
*
* Eccles, R., Jawad, M. S., and Morris, S. (1990). "The effects of oral administration of(-)-menthol on nasal resistance to airflow and nasal sensation of airflow in subjectssuffering from nasal congestion associated with the common cold." J Pharm Pharmacol**42**(9): 652-654.
*
* Edwars, G. M. H. a. L. D. (1944). "Nomenclature of Peppermint and Its Varieties." JOURNAL OF THE AMERICAN PHARMACEUTICAL ASSOCIATION: 333-342.
*
* Eickholt, T. H. a. B., R. H. (1965). "Toxicities of peppermint and Pycnanthemunalbescens oils, fam. Labiateae. ." J Pharm Sci.**54**(7): 1071-1072.
*
* El-Kady IA, E.-M. S., Mostafa ME. (1993). "Antibacterial and antidermatophyte activities of some essential oils from spices." Qatar University Science Journal**13**: 63-69.
*
* Fatiha Brahmi, M. K., Chibane Mohamed, Duez Pierre (2017). Chemical Composition and Biological Activities of Mentha Species. I. Limited.
*
* Freires I.A., D. C., Benso B., Matias de Alencar S. and Rosalen P.L. (2015). "Antibacterial Activity of Essential Oils and Their Isolated Constituents against Cariogenic Bacteria: A Systematic Review." Molecules**20**: 7329-7358.
*
* Giachetti, D., Taddei, E., and Taddei, I. (1986). "Pharmacological Activity of Menthapiperita, Salvia officinalis and Rosmarinus officinalis Essences on Oddi’s sphincter." Planta Medica**52**(6): 543-544.
*
* GO¬ KALP IúSüCAN, N. K., MIúNE KU¬ RKCU¬ OGÿ LU, K. HU¬ SNU¬ CAN BASüER, AND FATIúH DEMIúRCIú\* (2002). "Antimicrobial Screening of Mentha piperita Essential Oils." J. Agric. Food Chem.**50**: 3943-3946.
*
* Gobel, H., Fresenius, J., Heinze, A., Dworschak, M., and Soyka, D. (1996). "Effectiveness of Oleum menthae piperitae and paracetamol in therapy of headache of the tensiontype." Nervenarzt**67**(8): 672-681.
*
* Grigoleit, H. G. a. G., P. (2005). "Peppermint oil in irritable bowel syndrome." Phytomedicine**12**(8): 601-606.
*
* Hawthorn M, F. J., Luchowski E, Rutledge A, Wei XY, Triggle DJ. (1988). "The actions of peppermint oil and menthol on calcium channel dependent processes in intestinal, neuronal and cardiac preparations." Alimentary Pharmacology & Therapeutics**2**: 101-118.
*
* Henley-Smith C.J., B. F. S. a. L. N. (2013). "The use of plants against oral pathogens." Microbial pathogens and strategies for combating them: science, technology and education (A. Méndez-Vilas, Ed.).
*
* Hiki, N., Kurosaka, H., Tatsutomi, Y., Shimoyama, S., Tsuji, E., Kojima, J.,Shimizu, N., Ono, H., Hirooka, T., Noguchi, C., Mafune, K., and Kaminishi, M. (2003). "Peppermint oil reduces gastric spasm during upper endoscopy: a randomized, dou-ble-blind, double-dummy controlled trial." Gastrointest. Endosc.**57**(4): 475-482.
*
* I., O. P. a. T. (1984). " Neurotoxicity in rats dosed with peppermint oil andpulegone." Disease, Metabolism and Reproduction in the Toxic Response to Drugs andOther Chemicals **7**: 408-409.
*
* Janssen AM, C. N., Scheffer JJ, Baerheim Svendsen A. (1986). "Screening for antimicrobial activity of some essential oils by the agar overlay technique." Pharm Weekbl [Sci] **8**: 289-292.
*
* Kabra P., K. L. K., Shri Krishna Kabra S., Dipak Sadan Paul Majumdar and Neeraj Kumar (2012). "Medicinal Plants in the Treatment of Dental Caries." Asian Journal of Oral Health & Allied Sciences**2**(1).
*
* Kasem R.F., H. R. H., Arafa M.A.A., Abdel-Mohsen M.M. (2014). "Chemopreventive effect of Mentha piperita on dimethylbenz[a]anthracene and formaldehyde-induced tongue carcinogenesis in mice (histological and immunohistochemical study)." J Oral Pathol Med.
*
* Keifer D., U. C., Abrams T.R., Basch E., Giese N., Giles M., Kirkwood C.F., Woods M.M.J. (2007). "Peppermint (Mentha ×piperita): An evidence-based systematic review by the Natural Standard Research Collaboration,." Journal of Herbal Pharmacotherapy**7**(2).
*
* Kermanshah H., K. S. S. H., Arami S., Mohammad Kamalinegad M., Karimi M.,Mirsalehian A., Jabalameli F., Fard M.J.K. (2014). "The Effect of Hydro Alcoholic Extract of Seven Plants on Cariogenic Bacteria-An in Vitro Evaluation." OHDM **13** (2).
*
* Loolaie M., M. N., Rasouli H. and Adibi H. (2017). "Peppermint and Its Functionality: A Review." ARCHIVES OF CLINICAL MICROBIOLOGY **8** (4): 54.
*
* M., B. (1996). An encyclopedia of natural healing for children & infants. C. New Canaan, Keats Publishing, Inc.
*
* M., B. (1998). The complete German Commission E monographs : therapeutic guide to herbal medicines. . Austin, American Botanical Council.
*
* Madsen, C., Wurtzen, G., and Carstensen, J. (1986). "Short-term toxicity study in ratsdosed with menthone." Toxicol Lett.**32**(1-2): 147-152.
*
* Moleyar V, N. P. (1992). " Antibacterial activity of essential oil components. ." Int J of Food Microbiology**16**: 337-342.
*
* Monograph, M. p. f.-W. H. (2011). **Scribd, available at** [**www.scribd.com/.../Mentha-piperita-folium**](http://www.scribd.com/.../Mentha-piperita-folium) **WHO Herbal Monograph, accessed on 20th July**.
*
* Morice, A. H., Marshall, A. E., Higgins, K. S., and Grattan, T. J. (1994). "Effect of inhaled menthol on citric acid induced cough in normal subjects. ." Thorax**49**(10): 1024-1026.
*
* MT., M. (1995). The healing power of herbs : the enlightened person's guide to the wonders of medicinal plants. . C. Rocklin, Prima Pub.
*
* N., F. (1027). "Effect of camphor, eucalyptol and menthol on the vascular state of the mucousmenbrane." Archiv. Otolaryngol Head Neck Surg.**6**(112-122).
*
* Pattnaik S, S. V., Bapaji M, Kole CR. (1997). "Antibacterial and antifungal activity of aromatic constituents of essential oils." Microbios**89**: 39-46.
*
* Pattnaik S, S. V., Kole C. (1996). "Antibacterial and antifungal activity of ten essential oils in vitro. ." Microbios**86**: 237-246.
*
* Petrović M.S., K. L. G., Kitić D.V., Milašin J.M., Obradović R.R., Bojović M.D., Simonović A.A. (2015). "Periodontal Disease and Phytotherapy." Journal of Oral Hygiene & Health**3**(1): 172.
*
* pharmacopoeia, A. (1985). S. T. R. Commission. Lagos, Organization of African Unity. **1**.
*
* pharmacopoeia, B. (1995). International edition and addendum. London, Majesty’s Stationery Office. **1**.
*
* pharmacopoeia, E. (1996). Strasbourg, Council of Europe.
*
* Pimentel, M., Bonorris, G. G., Chow, E. J., and Lin, H. C. (2001). "Peppermint oil im-proves the manometric findings in diffuse esophageal spasm." J Clin Gastroenterol.**33**(1): 27-31.
*
* R., E. (1994). " Menthol and related cooling compounds." J Pharm Pharmacol **46**: 618-630.
*
* Raghavan R., D. M. P. S., Varghese M., Joseph A., Madhavan S.S.,Sreedevi P.V. (2018). "Effectiveness of Mentha piperita Leaf Extracts against Oral Pathogens: An in vitro Study." The Journal of Contemporary Dental Practice**19**(9): 1042-1046.
*
* Raudenbush B, K. J., Meyer B, 2002. (2002). "Flower N: Effects of ambient odor on pain threshold, pain tolerance, mood, workload, and anxiety." In Second Annual Meeting of the Society for Psychophysiological Research. Washington DC: Society for Psychophysiological Research;.
*
* Robbers JE, T. V. x., 287. (1999). Tyler's Herbs of choice : the therapeutic use
* of phytomedicinals. . Haworth Herbal Press. New York:, Haworth Herbal Press, **:** 287.
*
* Samber N., V. A., Manzoor N. (2014). "Evaluation of Mentha piperita Essential Oil and its Major Constituents for Antifungal Activity in Candida spp." International Journal of Innovative Research in Science, Engineering and Technology**3**(2).
*
* Singh R., M. A. M. S., Asma Belkheir (2015). "Antibacterial and antioxidant activities of Mentha piperita L." Arabian Journal of Chemistry**8**: 322-328.
*
* Singh R., S. M. A., Asma Belkheir A. (2015). "Antibacterial and antioxidant activities of Mentha piperita L." Arabian Journal of Chemistry**8**: 322-328.
*
* Soković M.D., J. V., Petar D. Marin, Dejan D. Brkić, Vlatka Vajs, and Leo J. L. D. van Griensven (2009). "Chemical Composition of Essential Oils of *Thymus* and *Mentha* Species and Their Antifungal Activities." Molecules**14**: 238-249.
*
* T., F. (1998). PDR for herbal medicines. . N. Montvale, Medical Economics Company, Inc.
*
* Thorup, I., Wurtzen, G., Carstensen, J., and Olsen, P. (1983). " Short term toxicity studyin rats dosed with peppermint oil." Toxicol Lett.**19**(3): 211-215.
*
* WHO, W. H. O. (1998). Quality control methods for medicinal plant materials. Geneva.
*
* Wyllie, J. P. a. A., F. W. (1994). "Nasal instillation of ‘Olbas Oil’ in an infant." Arch Dis Child**70**(4): 357-358.
*